VIM and adenocarcinoma: In summary, it is known that each of the four monoclonal antibodies directed against PR, ER, Vim, and CEA as well as a pre-existing panel, comprised of either 3 members (ER, Vim, CEA) or 4 members (PR, ER, Vim, CEA), could help in distinguishing between adenocarcinomas of endocervical origin and adenocarcinomas of endometrial origin.